Skip to main content
Premium Trial:

Request an Annual Quote

Investment Firm Upgrades Affy Stock Despite Disappointing Q1 Results

NEW YORK, April 24 (GenomeWeb News) - Investment firm Global Brown Capital upgraded Affymetrix's stock to "Overweight" from "Underweight" today despite the microarray company's disappointing first-quarter revenue and earnings, announced late last week.

 

The upgrade comes one business day after investment bank Deutsche Securities downgraded the stock to "Hold" from "Buy."

 

As GenomeWeb News reported last week,Affymetrix said that first-quarter sales declined more than 10 percent as overall revenue fell 2.5 percent year over year amid growing R&D expenses and shrunken profits.

 

The results caused shares in the company to fall 19 percent briefly to $27.54, a new 52-week low, though they closed at $29.03. Today the stock was up nearly half a percent, or $.12, at $29.15 in mid-afternoon trading. Affy's stock has lost more than half its value since early July last year.

 

Two days earlier, the company said Sue Siegel, president since 1999,  has resigned.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.